Trending...
- FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
- Heritage at Manalapan Welcomes New Sales Team as Luxury Single-Family Home Community Continues to Grow
- Parents No Longer Have to Wait 3 Weeks for a Sleep Consultant: Nora Talks Tonight, Stays for 5 Days, Costs $89
DURHAM, N.C.--(BUSINESS WIRE)--KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, announced today the establishment of a new commercial manufacturing facility in Research Triangle Park (RTP) in North Carolina. KBI expects the $150 million, 140,000-square-foot facility to be operational by Q1 2022. The site will host more than 200 technical positions in operations and quality assurance. KBI is co-investing in the facility with an undisclosed pharmaceutical partner to support manufacturing of their therapeutic protein programs.
"Expansion of our US-based cell culture operations is a key investment to support our clients' commercialization strategies," said KBI President and CEO Dirk Lange. "This state-of-the-art facility will leverage the latest innovation in automation and digitalization to best meet the needs for our clients."
In addition to providing cGMP biologics manufacturing for its co-investor, KBI will also use the new North Carolina facility as a commercialization option for KBI's existing and future partners. The new turn-key, design-build construction will utilize KBI's proven single-use platform and provide supply reliability with redundant equipment, automation, and full utility backup. The design enables flexibility to accommodate a variety of mammalian-based biologics manufacturing processes. It also includes a ring corridor for suite access and a "science on display" viewing corridor to showcase the facility to KBI partners.
The new RTP location will house up to six 2,000-liter, single-use bioreactor systems and associated harvest and purification equipment, which can produce more than 100 commercial batches annually. In tandem with the manufacturing operations, KBI will employ advanced analytical services for commercial product characterization and release testing capabilities to support commercial launch and routine supply.
More on ncarol.com
Following the JSR Life Sciences ONEDigital initiative, the new facility will incorporate Manufacturing 4.0 principles through the design and integration of advanced technologies. The digital plant will feature data collection systems, including electronic batch records, electronic logbooks, paperless materials management, and Laboratory Information Management Systems (LIMS) for quality control data management. These tools will enable real-time process and product quality monitoring and allow for future AI technology adoption.
"KBI has helped to advance more than 300 molecules in more than 70 unique indications. By expanding our commercial manufacturing footprint with this facility, we are able to provide our partners with launch material and market supply," continued Mr. Lange. "We chose to build this new facility in the Research Triangle Park because it gives us access to highly-specialized resources. The combination of talent, technical and academic training in this region is outstanding, which is critical as we are expanding our impact by serving more clients and patients from this new facility."
The new site is located in close proximity to KBI's RTP mammalian drug development labs in Patriot Park, a new multi-phase industrial park developed by Indianapolis-based Strategic Capital Partners. KBI collaborated closely with Cushman & Wakefield to secure this building near the Raleigh-Durham (RDU) International Airport.
This is the second major facility expansion announced by KBI. Last month, the Company announced a new 5,600-square-meter biologic bulk drug substance manufacturing facility in Geneva, Switzerland. That facility is scheduled to be operational by mid-2022 and will create more than 200 positions in development, operations, and quality assurance.
More on ncarol.com
About KBI Biopharma, Inc.
KBI Biopharma, a JSR Life Sciences company, is an award-winning biopharmaceutical contract services organization providing fully integrated, accelerated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally. With each of our 300+ client partners, we have worked closely to personalize and rapidly accelerate their drug development programs. Built upon a foundation of world-class analytical capabilities, we deliver efficient process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. We have locations in Durham and Research Triangle Park (NC), Boulder and Louisville (CO), The Woodlands (TX), and Leuven, Belgium. More information is available at www.kbibiopharma.com
"Expansion of our US-based cell culture operations is a key investment to support our clients' commercialization strategies," said KBI President and CEO Dirk Lange. "This state-of-the-art facility will leverage the latest innovation in automation and digitalization to best meet the needs for our clients."
In addition to providing cGMP biologics manufacturing for its co-investor, KBI will also use the new North Carolina facility as a commercialization option for KBI's existing and future partners. The new turn-key, design-build construction will utilize KBI's proven single-use platform and provide supply reliability with redundant equipment, automation, and full utility backup. The design enables flexibility to accommodate a variety of mammalian-based biologics manufacturing processes. It also includes a ring corridor for suite access and a "science on display" viewing corridor to showcase the facility to KBI partners.
The new RTP location will house up to six 2,000-liter, single-use bioreactor systems and associated harvest and purification equipment, which can produce more than 100 commercial batches annually. In tandem with the manufacturing operations, KBI will employ advanced analytical services for commercial product characterization and release testing capabilities to support commercial launch and routine supply.
More on ncarol.com
- Who Is KayeDinero? The Asheville Artist Also Builds Software and Trading Systems
- Leaping Cat Creative Takes Shape Around the Problems Nobody Quite Owns
- White Coat Financial Partners Announces Launch of Next Generation Practice Optimization Software
- Kerri Lawless Introduces New Home-Selling Option for Local Homeowners
- As Boone Takes Art to the Streets, KayeDinero Asks What Makes Creativity Human
Following the JSR Life Sciences ONEDigital initiative, the new facility will incorporate Manufacturing 4.0 principles through the design and integration of advanced technologies. The digital plant will feature data collection systems, including electronic batch records, electronic logbooks, paperless materials management, and Laboratory Information Management Systems (LIMS) for quality control data management. These tools will enable real-time process and product quality monitoring and allow for future AI technology adoption.
"KBI has helped to advance more than 300 molecules in more than 70 unique indications. By expanding our commercial manufacturing footprint with this facility, we are able to provide our partners with launch material and market supply," continued Mr. Lange. "We chose to build this new facility in the Research Triangle Park because it gives us access to highly-specialized resources. The combination of talent, technical and academic training in this region is outstanding, which is critical as we are expanding our impact by serving more clients and patients from this new facility."
The new site is located in close proximity to KBI's RTP mammalian drug development labs in Patriot Park, a new multi-phase industrial park developed by Indianapolis-based Strategic Capital Partners. KBI collaborated closely with Cushman & Wakefield to secure this building near the Raleigh-Durham (RDU) International Airport.
This is the second major facility expansion announced by KBI. Last month, the Company announced a new 5,600-square-meter biologic bulk drug substance manufacturing facility in Geneva, Switzerland. That facility is scheduled to be operational by mid-2022 and will create more than 200 positions in development, operations, and quality assurance.
More on ncarol.com
- FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
- Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
- Black Mountain Meets "Human Error": KayeDinero on What Technology Can't Reproduce
- As Brevard Heads Into Mountain Song Weekend, KayeDinero Brings a Different Kind of WNC Sound
- Why Did KayeDinero Put Haywood Road Into a Song?
About KBI Biopharma, Inc.
KBI Biopharma, a JSR Life Sciences company, is an award-winning biopharmaceutical contract services organization providing fully integrated, accelerated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally. With each of our 300+ client partners, we have worked closely to personalize and rapidly accelerate their drug development programs. Built upon a foundation of world-class analytical capabilities, we deliver efficient process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. We have locations in Durham and Research Triangle Park (NC), Boulder and Louisville (CO), The Woodlands (TX), and Leuven, Belgium. More information is available at www.kbibiopharma.com
0 Comments
Latest on ncarol.com
- Defense & Space Strategy Strengthens as New Leadership Builds on NASA Results and Expanding Multi-Orbit Opportunities for Ascent Solar Technologies
- STS Capital Partners is pleased to announce the appointment of Barry Brown as Vice President, Business Development
- Local Ecomaids Owner Launches Healthy Home Reset Initiative for Triangle Families
- Qscription Technologies and NEOPATHOLOGY CORP. Sign MOU to Bring FDA-Cleared Lung Imaging AI into U.S. Clinical Practice
- Asheville Artist KayeDinero Asks What Happens When Technology Gets Too Human on "Human Error"
- Heritage at Manalapan Welcomes New Sales Team as Luxury Single-Family Home Community Continues to Grow
- Mandeville Pests May Pose Serious Health Risks for Your Family
- TOLI North America's Floorleum Plain AdVantage Transforms Flooring Into a Wayfinding Tool
- Share your workplace safety solutions at 2027 Applied Ergonomics Conference
- Parents No Longer Have to Wait 3 Weeks for a Sleep Consultant: Nora Talks Tonight, Stays for 5 Days, Costs $89
- May The Worst Team Win! Loserball Kicks Off Another NFL Season of Hilarious Mayhem
- Black Women Living With, and Impacted by, HIV Express Gratitude, Grief, Joy, and Resilience
- MainConcept Easy Video API Extends Full Transcoding to Arm and NETINT VPUs
- From Detroit Streets to Blue Ridge Mountains: KayeDinero Finds a New Sound in Western North Carolina
- Why Did KayeDinero Name a Song After Hendersonville?
- Cruxy shortlisted for two Private Equity Wire® US Awards 2026: Advisory Firm of the Year (Overall) & Value Creation Consulting Firm of the Year
- Did Asheville's BoomTown Weekend Inspire KayeDinero's Next Move?
- From City Girl to Mountain Life: KayeDinero Releases "City Girl Saved" From Asheville
- Lake Norman Philharmonic - Free Community Concert
- Amaris Mint® Confirms UK Availability of Swedish-Made BioBoost Daily Nutrition Range